J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech. Reported by Endpoints News on 2026-07-30.
Sail Biomedicines
Private
Sail Biomedicines is a Flagship Pioneering-backed in vivo CAR-T biotech engineering mRNA-encoded therapeutics to treat autoimmune disease and cancer. The company is developing programmable medicines that instruct the body to produce its own therapeutic proteins inside target cells.
Company Info
Upcoming Milestones & Key Dates
2026
Regulatory
IND-enabling studies for lead autoimmune CAR-T candidate
2027
Clinical
Anticipated first-in-human study initiation
Clinical Development Pipeline
Undisclosed
Target: CAR-T (in vivo, mRNA-encoded)Undisclosed
Target: CD19-directed in vivo CAR-TUndisclosed
Target: In vivo CAR-TRecent News
J&J secures right to take the helm in up to $925M Sail CAR T pact
J&J secures right to take the helm in up to $925M Sail CAR T pact. Reported by BioSpace on 2026-07-30.
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Scientific Officer
To be confirmed
Chief Medical Officer